ABRAXANE Meets Primary Endpoint in Phase III CA033 Study

Celgene said its unit Celgene International Sàrl announced results of its Phase III, randomized, international study of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in chemotherapy-naïve patients with metastatic melanoma.
RTTNews